Zbtb7b defines a compensatory mechanism in MASLD ‐related HCC progression by suppressing H19 ‐mediated hepatic lipid deposition
Physiological Reports · 2024
DOI: 10.14814/phy2.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, 2024. Verfasst von Yinglin Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Di…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), National Natural Science Foundation of China (NSFC), Science and Technology Commission of Shanghai Municipality (STCSM).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a widely prevalent type of primary liver cancer. However, strategies for pretumor intervention are still limited. In this study, a liver‐specific Zbtb7b knockout mouse model was used to evaluate the role of Zbtb7b in metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related HCC development. We revealed that Zbtb7b was compensatively increased and restricted lipid deposition in the liver during MASLD progression, which protects against MASLD‐related HCC initiation. Mechanistically, Zbtb7b suppresses the expression of the long noncoding RNA H19 to attenuate hepatic de novo lipogenesis and increase fatty acid oxidation, thereby preventing lipid accumulation in hepatocytes. As a result, the proliferation and migration abilities of HCC cells are reduced. Overall, we demonstrated that Zbtb7b serves as a tumor suppressor at an early stage of HCC, thus providing a promising target for the treatment of HCC at a premalignant stage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Shangha…
- Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Endocrinology and Metabolism, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai Medical College, Shanghai, China.
ORCID-Profile: Yinglin Han, Xu-Yun Zhao
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- National Natural Science Foundation of China (NSFC)
- Science and Technology Commission of Shanghai Municipality (STCSM)
- Innovative research team of high-level local universities of Shanghai
- National Key Research and Development Program of China
Zitieren
APA
Han, Y., Wu, K., Peng, X., Fu, Y., Li, W., Ma, J., Jiang, H., & Zhao, X. Y. (2024). Zbtb7b defines a compensatory mechanism in MASLD ‐related HCC progression by suppressing H19 ‐mediated hepatic lipid deposition. Physiological Reports. https://doi.org/10.14814/phy2.70160
Vancouver
Han Y, Wu K, Peng X, Fu Y, Li W, Ma J, et al. Zbtb7b defines a compensatory mechanism in MASLD ‐related HCC progression by suppressing H19 ‐mediated hepatic lipid deposition. Physiological Reports. 2024. doi:10.14814/phy2.70160
BibTeX
@article{Han2024,
author = {Han, Yinglin and Wu, Kaimin and Peng, Xin and Fu, Yinkun and Li, Wenyan and Ma, Jing and Jiang, He and Zhao, Xu-Yun},
title = {Zbtb7b defines a compensatory mechanism in MASLD ‐related HCC progression by suppressing H19 ‐mediated hepatic lipid deposition},
journal = {Physiological Reports},
year = {2024},
doi = {10.14814/phy2.70160}
}
EUVIMED